



ViennaLab Diagnostics is part of the MedPhab consortium funded by a Horizon 2020 research grant. [link: https://medphab.eu]

The MedPhab Project

MedPhab serves as Europe's first Pilot Line dedicated to manufacturing, testing, validation and up-scaling of new photonics technologies for medical diagnostics. The purpose of MedPhab pilot production line is to accelerate the commercialization of diagnostic devices and instruments for treatment based on photonics, and to reduce the R&D costs. Such project needs the cooperation of a consortium of excellent research institutes and companies with experience in ISO 13485 standardized manufacturing and strong expertise in photonics. The technology readiness and MedPhab operation process will be validated by:

- **Use-Case** Validation program (MedPhab Partners), upscaling and demonstrating performance of 5 innovative medical diagnostics products;
- Demo-Case Open Calls program, enabling early adoption of the technologies by external users, demonstrating the pilot line services and validating the open access business model. Other MedPhab partners are VTT (FI), Joanneum Research (AT), IMEC (BE), CSEM (CH), Philips (NL), Jabil (AT), Tyndall (iE), Screentec (FI), III-V Lab (FR), Stryker (IE), POLAR (FI), Radisens Diagnostics (IE), Meep (BE), Genspeed Biotech (AT), NKI (NL), EPIC (FR) and AMIRES (CZ).

MedPhab Open Call:

MedPhab is launching an Open Call for external companies developing medical products. The objective of the Open Call is to provide technology development services for the companies that are adopting advanced photonics technologies in the medical diagnostics solutions. As the technology development services are pioneering in nature, MedPhab provides subsidized financial support to up to **20 business cases**. For small and medium enterprises (SMEs) the support is 75% of the costs and for large enterprises the support is 50%.

More information on Open Call is provided here:

[link: https://medphab.eu/open-call]